Login to Your Account



Potential Total Value: $1.7B

Cephalon Bets on Stem Cells with $350M Mesoblast Deal

By Catherine Shaffer


Thursday, December 9, 2010
Cephalon Inc. is betting that its short-term $350 million investment in stem cell technology will help to plug a much more expensive hole with the April 2012 patent expiration of its sleep disorder drug Provigil.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription